ICU Medical stock dips after CFO share sale as investors eye 2026 guidance

ICU Medical, Inc. (ISIN US44930G1076) stock was quoted at 170.81 US dollars as of September 2, 2026, down 1.24% from the prior close according to market data compiled by Yahoo Finance, leaving the company’s market capitalization at about 4.271 billion US dollars.

Insider sale puts attention on valuation

A fresh catalyst for ICU Medical stock is a significant insider transaction: the company’s Chief Financial Officer Brian Michael Bonnell sold 6,381 shares of common stock at 175.00 US dollars per share on September 1, 2026, as reported in a Form 4 filing summarized by StockTitan and MarketScreener.

According to StockTitan’s overview of the Form 4, the total value of the transaction was approximately 1,116,675 US dollars, with all 6,381 shares sold at the same 175.00 US dollars price in an open-market or private transaction recorded with sale code S.

Guidance and latest earnings context

Beyond insider activity, investors are tracking the company’s profit outlook. A same-day summary on MarketBeat notes that ICU Medical has set its fiscal year 2026 earnings per share guidance in a range of 8.600 to 9.000 US dollars.

That guidance range, if achieved, implies that the current share price of 170.81 US dollars as of September 2, 2026 values ICU Medical at approximately 19 to 20 times the midpoint of the expected 2026 EPS, a level that will be closely watched in comparison with other medical instruments and supplies peers.

Peer comparison and DACH relevance

ICU Medical operates in the medical instruments and supplies industry and is listed on the Nasdaq under the ticker ICUI; several European peers such as Getinge AB and CONMED Corporation are tracked by investors for sector context, with Getinge B shares trading in Swedish krona and CONMED listed on the New York Stock Exchange.

Market data on CONMED Corporation and on Getinge B underline that ICU Medical’s valuation and guidance are being read within a broader global medtech sector, which is also relevant for investors in the DACH region who follow listed healthcare technology groups on exchanges such as Xetra and SIX Swiss Exchange.

Infusion therapy and device portfolio

ICU Medical is best known for its portfolio of infusion therapy products, including sterile closed system transfer devices and needle-free connectors designed to reduce infection risk and improve safety in hospital settings.

These devices form a key part of the company’s revenue base by supporting oncology, intensive care and general hospital wards globally, and they anchor the long-term investment case that underpins its 2026 EPS guidance and current trading range.

Stock price snapshot and trading context

As of the latest quote on September 2, 2026, ICU Medical stock at 170.81 US dollars, with a 52-week low of 112.50 US dollars and a 52-week high of 192.85 US dollars according to MarketBeat’s same-day data, is positioned in the upper half of its yearly trading range on the Nasdaq.

With the shares still below the 52-week high yet well above the low, and with a market capitalization of 4.271 billion US dollars as of September 2, 2026, the insider sale and 2026 EPS guidance frame the current risk-reward profile for investors watching ICU Medical stock alongside other international medtech names.

ICU Medical key data

• Company: ICU Medical, Inc.
• ISIN: US44930G1076
• Ticker: ICUI
• Trading venue: Nasdaq
• Price (as of September 2, 2026, 07:00): 170.81 USD
• Market capitalization: 4.271 billion USD (as of September 2, 2026)
• Sector / Industry: Medical instruments and supplies
• Index membership: S&P 400 MidCap